ORIC at a glance
Oric Pharmaceuticals, Inc. (ORIC, SEC CIK 1796280) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Oric Pharmaceuticals, Inc. (ORIC) shares worth $515.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Heyman Richard A. on October 1, 2026 of 3,500 shares at $12.91 per share.
- In the last 90 days, ORIC insiders reported 0 open-market purchases ($0) and 8 open-market sales ($1.5M) on Form 4, a net sale of $1.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$1.5M
- 13F holders
- 26 funds
- $515.0M · +0 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No revenue generated in Q2 2026 or comparable Q2 2025
- Net loss $41.5M vs $36.4M YoY
- R&D expense $36.3M vs $30.5M, led by rinzimetostat costs $16.0M vs $7.3M
- Operating cash outflow $64.0M through June 2026 vs $63.4M YoY
- ATM proceeds $59.9M through June; cash expected to fund operations into second half of 2028
Risk Factors
- No explicit new or changed risk factors disclosed versus the most recent 10-K
- Cash, cash equivalents and investments $387.6M at June 30, 2026, funding operations into second half of 2028
- Regulatory approval uncertainty: FDA Project Optimus may alter oncology dose-selection requirements during development
- Clinical-stage dependence: rinzimetostat and enozertinib require additional trials, manufacturing expansion and regulatory approval
- Financial losses: $77.3M net loss for six months ended June 30, 2026, with accumulated deficit of $769.5M
AI summary of the ORIC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 financial results announced
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Phase 3 Himalayas-1 initiated in approximately 600 mCRPC patients across 25 countries, materially advancing rinzimetostat toward registration
- Bayer supplying NUBEQA at no cost, preserving ORIC’s full global rights while reducing trial drug-supply expense
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Additional 1,100,000 shares reserved, bringing total Inducement Plan capacity to 3,350,000 shares
- Equity awards issued without shareholder approval under Nasdaq inducement rules
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved amended 2020 Equity Incentive Plan effective June 18, 2026
- Annual share increase changed from 5% to 4% of outstanding common shares, but 2,656,500-share cap removed
Item 5.07: Submission of Matters to a Vote of Security Holders
- 91.36% shareholder participation; 94,571,281 shares represented at the June 18, 2026 annual meeting
- Class III directors Jacob M. Chacko and Mardi C. Dier elected through the 2029 annual meeting
AI summaries of ORIC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ORIC
Don't miss the next ORIC filing
- Alerts as it files. A push when ORIC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ORIC, by share count.
- Ask anything. An AI agent that reads every ORIC filing and answers with sources.
ORIC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Heyman Richard A. | Sell | Oct 1, 2026 | 3,500 | $12.91 |
| Heyman Richard A. | M | Oct 1, 2026 | 3,500 | - |
| Heyman Richard A. | M | Oct 1, 2026 | 3,500 | $1.60 |
| Heyman Richard A. | Sell | Oct 1, 2026 | 3,200 | $12.91 |
| Piscitelli Dominic | M | Sep 28, 2026 | 13,400 | - |
| Piscitelli Dominic | M | Sep 28, 2026 | 13,400 | $4.36 |
| Piscitelli Dominic | Sell | Sep 28, 2026 | 13,400 | $13.53 |
| Piscitelli Dominic | Sell | Sep 24, 2026 | 500 | $13.51 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$110.8M | -$142.9M | -$143.0M |
| Net Income | -$100.7M | -$127.8M | -$129.5M |
| Balance Sheet | |||
| Total Assets | $252.0M | $274.1M | $408.9M |
| Equity | $224.1M | $243.1M | $384.4M |
| ROE | -44.9% | -52.6% | -33.7% |
| Per Share | |||
| EPS | $-1.96 | $-1.83 | $-1.47 |
| Cash Flow | |||
| Operating CF | -$85.7M | -$112.7M | -$111.0M |
| CapEx | - | $1.2M | $712K |
Source: XBRL data in Oric Pharmaceuticals, Inc. (ORIC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ORIC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $515.0M |
| Q1 2026 | 26 | $550.1M |
| Q4 2025 | 23 | $347.0M |
| Q3 2025 | 24 | $463.7M |
| Q2 2025 | 26 | $334.6M |
| Q1 2025 | 22 | $133.4M |
| Q4 2024 | 17 | $162.2M |
| Q3 2024 | 15 | $90.1M |
- D.E. Shaw & Co+1.54M (+3460%)
- T. Rowe Price Group+1.23M (+23%)
- State Street Corp+1.19M (+32%)
- Goldman Sachs Group+976.1K (+66%)
- BlackRock+839.4K (+14%)
- Pfizer Inc−4.41M (-92%)
- Viking Global Investors−697.8K (-12%)
- Prudential Financial−77.2K (-80%)
- JPMorgan Chase & Co−15.3K (-5%)
- Invesco Ltd−1.2K (-1%)
- Two Sigma Investments+603.7K
- Allstate+16.2K
- PNC Financial Services−8.0K
- U.S. Bancorp−173
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ORIC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| SC 13G | May 15, 2026 | - | - | |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Mar 31, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| 10-K | Feb 23, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| SC 13G | Jan 21, 2026 | - | - | |
| 4 | Jan 20, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ORIC SEC filings: frequently asked questions
Are ORIC insiders buying or selling?
In the last 90 days, Oric Pharmaceuticals, Inc. (ORIC) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $1.5 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ORIC stock?
As of June 30, 2026, the largest Oric Pharmaceuticals, Inc. (ORIC) holders among the 13F filers tracked by SignalX were BlackRock ($73.9 million), T. Rowe Price Group ($71.7 million), Viking Global Investors ($55.5 million), State Street Corp ($53.0 million), Vanguard Capital Management LLC ($42.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ORIC report in its latest 8-K?
Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended June 30, 2026 financial results announced.
What are the latest ORIC SEC filings?
Oric Pharmaceuticals, Inc. (ORIC) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on October 2, 2026.
What is ORIC's SEC CIK number?
Oric Pharmaceuticals, Inc. (ORIC)'s SEC Central Index Key (CIK) is 1796280. EDGAR lists every ORIC filing under that number.
Ask anything about ORIC
The research agent reads ORIC's filings, financials, insider trades and 13F holders, then answers with sources.